ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
NICE backs restricted use of Ondexxya pharmatimes
April 07, 2021NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adults who experience a life-threatening or uncontrolled bleed in the ... -
NICE backs Portola's Ondexxya pharmatimes
September 14, 2020The National Institute for Health and Care Excellence (NICE) has published the outcome of an appraisal consultation document backing NHS funds for restricted use of Portola's Ondexxya (andexanet alfa) as an option for reversing anticoagulation ...
Pharma Sources Insight January 2025
